Islam Eljilany
YOU?
Author Swipe
View article: Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer
Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer Open
The incidence of colorectal cancer in young adults (age of diagnosis <50 years) has been rapidly increasing. Although ∼20% of early-onset colorectal cancer (EOCRC) cases are due to germline mutations, the etiology of the majority of EOC…
View article: Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Methods S1. Gene Expression Profiling (GEP), Peripheral Blood, Multiplex Serum Cytokine Analysis, Multicolor Flow Cytometry, Survival Analysis, LASSO Signature Training and Testing.
View article: Supplementary Figure S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S4. L-IPI7 Score predicts survival in an IO-treated cohort (N=123) of patients with metastatic melanoma.
View article: Supplementary Figure S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S3. Forest Plot Featuring high and low LIPI7 risk score vs. categorized gender and age with a median of 57 years.
View article: Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S6. Cross-validation curve.
View article: Supplementary Table S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Table S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Table S2. Patient Demographics and Baseline Disease Characteristics.
View article: Supplementary Table S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Table S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Table S1. Immune biomarkers analyzed in both tumor and circulating blood.
View article: Supplementary Figure S7 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S7 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S7. A forest plot of patients indicated as “High Risk” by having an above median LIPI7 risk score.
View article: Supplementary Figure S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S1. CONSORT diagram.
View article: Supplementary Figure S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S2. Survival analysis flowchart.
View article: Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Figure S5. Kaplan-Meier overall survival (OS) and recurrence-free survival (RFS) curves of 4 prioritized high-risk and low-risk features determined by the Cox proportional hazards regression analysis.
View article: Supplementary Table S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Table S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Table S4. Prioritized high and low-risk features determined by the Cox proportional hazards (PH) regression analysis.
View article: Data from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Data from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Purpose:Ipilimumab (IPI) improved outcomes for patients with high-risk melanoma compared with IFN-α2b in E1609, a phase III adjuvant trial. We hypothesized that combining candidate immune biomarkers in both tumor and circulating blood coul…
View article: Supplementary Table S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Supplementary Table S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma Open
Supplementary Table S3. Representativeness of Study Participants.
View article: Evaluating the economic impact of clinical pharmacist interventions in the women’s health setting in Qatar
Evaluating the economic impact of clinical pharmacist interventions in the women’s health setting in Qatar Open
Background Adverse drug events (ADEs) resulting from nonoptimized medication therapy significantly drive-up healthcare costs. Clinical pharmacists are pivotal in managing medication regimens, effectively reducing these associated expenses.…
View article: Epigenetic Modulation, Intra-tumoral Microbiome and Immunity in Early Onset Colorectal Cancer
Epigenetic Modulation, Intra-tumoral Microbiome and Immunity in Early Onset Colorectal Cancer Open
Background: The incidence of colorectal cancer (CRC) in young adults (age of diagnosis < 50 years old) has been rapidly increasing. Although ~20% of early-onset (EO) CRC cases are due to germline mutations, the etiology of the majority of …
View article: Table S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Table S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
Modeling results for gene expression differences between responders and non-responders
View article: Table S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Table S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
Correlations between microbe abundances and MSigDB Hallmark gene sets average Z scores
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Cox proportional hazards model results for the interaction terms between hypoxia (binary, low or high) with microbe relative abundance in COADREAD tumors treated with radiotherapy.
View article: Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
The list of published gene signatures compared between treatment responders and non-responders and to tumor microbe abundances.
View article: Figure S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Figure S5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
Comparison of alternate machine learning methods
View article: Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
Model performance of 31 published gene expression signatures for predicting immunotherapy treatment response
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Numbers at risk for the association between survival and Fusobacterium canifelinum abundance in COADREAD tumors treated with radiation.
View article: Supplementary Tables Legend from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Tables Legend from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Legend for Supplementary Tables
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Selected log2 fold change results for microbes found to be significantly enriched in hypoxic tumors in both mice and human subjects.
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Log2 fold changes of annotated Cutibacterium genes between hypoxic and normoxic tumors in nude and BALB/c mice.
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Correlations between tumor microbes enriched in hypoxic tumors in both mice and humans and deconvolved immune cell abundances.
View article: Figure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Figure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors Open
Comparison with TCGA for microbes most significantly enriched in response groups
View article: Supplemental Figure S1 from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplemental Figure S1 from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Hypoxia scores by stage (A) or sex (B) for the ORIEN radiation-treated cohort.
View article: Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer
Supplementary Data from The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer Open
Fold-changes and adjusted p-values for all microbes associated with hypoxic or normoxic tumors in the ORIEN and TCGA datasets (associated with Figure 2A). Results of survival analyses of interactions between microbes and hypoxia in COADREA…